Andrew J Head MD FACR

Rheumatology•Cincinnati, OH

Lupus & Related, Rheumatoid Arthritis & Related, Scleroderma & Related, Spondyloarthropathy

Medical Director-Immune Mediated Inflammatory Diseases-Rheumatology Medpace Cincinnati, OH

Join to View Full Profile

5375 Medpace WayCincinnati, OH 45227
Phone+1 513-579-9911
Fax+1 513-579-0444

Education & Training

University of TennesseeFellowship, Rheumatology, 2002 - 2004
Christ HospitalResidency, Internal Medicine, 1998 - 2001
University of Cincinnati College of MedicineClass of 1998

Certifications & Licensure

MI State Medical License 2004 - 2026
OH State Medical License 1999 - 2026
TN State Medical License 2002 - 2004
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Fellow (FACR) American College of Rheumatology

Clinical Trials

An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2013 Jun 27
Completed
Phase 3
A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
Terminated
Phase 2
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Start of enrollment: 2019 Apr 25
ACTIVE_NOT_RECRUITING
PHASE4
A Study in Moderate to Severe Rheumatoid Arthritis Participants Start of enrollment: 2012 Dec 01
Completed
Phase 3
A Moderate to Severe Rheumatoid Arthritis Study Start of enrollment: 2013 Jan 01
Completed
Phase 3
Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2016 Jun 30
Completed
Phase 3
Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Start of enrollment: 2015 Jun 09
Completed
Phase 3
AMG 827 in Subjects With Psoriatic Arthritis Start of enrollment: 2011 Oct 01
Terminated
Phase 2
A Study of LY2127399 in Participants With Systemic Lupus Erythematosus Start of enrollment: 2010 Dec 01
Completed
Phase 3
Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc) Start of enrollment: 2008 Oct 01
Terminated
Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) Start of enrollment: 2006 Mar 01
Completed
Phase 2
A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus Start of enrollment: 2004 Oct 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

9 citations
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Therapy in Rheumatoid Arthritis.
Richard J. Martin, Ryan D Enck, Donald J. Tellinghuisen, Aaron T Eggebeen, James D Birmingham
Medical Decision Making. 2017-03-15
19 citations
Influence of patient characteristics on perceived risks and willingness to take a proposed anti-rheumatic drug.
Richard J. Martin, Kelsey McCallops, Andrew J Head, Aaron T Eggebeen, James D Birmingham
BMC Medical Informatics and Decision Making. 2013-08-12
39 citations
Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician.
Richard J. Martin, Andrew J Head, Jonathan René, Timothy J Swartz, Justus J Fiechtner
The Journal of Rheumatology. 2008-04-01

Press Mentions

Top DoctorsJanuary 16th, 2023

Professional Memberships

American College of Rheumatology - ACR
Fellow

Andrew J Head MD FACR

Dr. Head is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.